Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | London | Healthcare | Pharmaceuticals | £288.86B | 104.6x | -4.14 | GBX 19,334.19 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £208.64B | 23.4x | -2.14 | GBX 25,503.97 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £208.64B | 23.4x | -2.15 | GBX 24,345.55 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £192.94B | 14.9x | 0.64 | GBX 4,390.89 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £177.11B | 18x | -1.37 | GBX 9,115.10 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £173.93B | 28.4x | 0.99 | GBX 11,210 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.8% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £147.83B | 12.3x | 0.61 | GBX 5,915.34 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £104.63B | 22.6x | 0.05 | GBX 8,473.86 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £84.49B | 15.5x | 0.13 | GBX 6,956.26 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £59.77B | 18x | -1.14 | GBX 1,485 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £41.04B | 16.4x | 1.77 | GBX 9,463.83 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB L | London | Healthcare | Pharmaceuticals | £33.91B | 29.9x | 0.06 | GBX 17,901.24 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £29.54B | 21.9x | 0.48 | GBX 330.30 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27% Upside | Upgrade to Pro+ | |
Bayer L | London | Healthcare | Pharmaceuticals | £23.69B | -7.9x | 0.05 | GBX 2,415.93 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £18.99B | 114.6x | 0.04 | GBX 4,405.74 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £14.95B | 13.1x | 0.43 | GBX 10,187.32 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.42B | 26.9x | 5.17 | GBX 4,576.12 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £8.18B | 21.5x | -0.62 | GBX 10,059.08 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £8.17B | 24.8x | 0.4 | GBX 5,777.97 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £7.61B | 22x | 0.22 | GBX 2,198.57 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | London | Healthcare | Pharmaceuticals | £6.42B | 27.1x | 0.18 | GBX 735.77 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £6.41B | 27.1x | 0.18 | GBX 1,067.44 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £5.36B | 46.1x | 0.85 | GBX 1,748.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
H Lundbeck L | London | Healthcare | Pharmaceuticals | £5.07B | 11.1x | 0.35 | GBX 532.15 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £4.04B | 8.3x | -1.14 | GBX 1,125.97 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £3.89B | 39x | 1.24 | GBX 27,864.43 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £3.58B | 13.1x | 0.42 | GBX 1,613 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £3.20B | 56.8x | 0.27 | GBX 5,399.43 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.28B | 19.6x | -3.61 | GBX 27,209.71 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Almirall | London | Healthcare | Pharmaceuticals | £2.16B | 114.2x | 0.72 | GBX 1,002.85 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £1.98B | 5.9x | 0.01 | GBX 230 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.2% Upside | Upgrade to Pro+ | |
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.33B | 53.3x | GBX 7,733.05 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Fagron NV | London | Healthcare | Pharmaceuticals | £1.25B | 16.7x | 1.77 | GBX 1,700.22 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faes Farma | London | Healthcare | Pharmaceuticals | £1.15B | 12.5x | 1.55 | GBX 368.32 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £972.38M | 19x | GBX 6,107.82 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biogaia AB | London | Healthcare | Pharmaceuticals | £874.84M | 38.5x | -1.33 | GBX 864.17 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Uniphar | London | Healthcare | Pharmaceuticals | £872.44M | 16.5x | 0.3 | GBX 335 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | |
Medincell | London | Healthcare | Pharmaceuticals | £650.48M | -36.2x | -1.3 | GBX 1,970.79 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Pharmaceuticals | £395.61M | -11.1x | -0.15 | GBX 8.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £320.67M | 8.1x | 0.28 | GBX 46.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Niox PLC | London | Healthcare | Pharmaceuticals | £305.85M | 96.3x | -1.39 | GBX 73.20 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.9% Upside | Upgrade to Pro+ | |
Animalcare | London | Healthcare | Pharmaceuticals | £171.64M | 31.9x | 0.03 | GBX 250 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32% Upside | Upgrade to Pro+ | |
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £132.29M | -2x | 0.03 | GBX 1,053.04 | -11.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Photocure | London | Healthcare | Pharmaceuticals | £114.44M | -289.8x | 2.08 | GBX 437.55 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotec Pharmacon | London | Healthcare | Pharmaceuticals | £97.19M | 475x | -5.98 | GBX 192.19 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shield Therapeutics | London | Healthcare | Pharmaceuticals | £78.35M | -4.2x | -0.11 | GBX 7.38 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £70.43M | -2,750x | 19.81 | GBX 55 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £62M | 37.7x | 0.59 | GBX 91.50 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.51M | -4.5x | GBX 12.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Probiotix | Aquis Exchange | Healthcare | Pharmaceuticals | £12.26M | -15.4x | GBX 7.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |